Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. by Mesturini, R. et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in CYTOKINE, 64, 2013,
10.1016/j.cyto.2013.05.021.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.cyto.2013.05.021
The publisher's version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S1043466613002676
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/139889
 
 1 
Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1 
 
Riccardo Mesturini, Casimiro L. Gigliotti, Elisabetta Orilieri, Giuseppe Cappellano, Maria F. Soluri, 
Elena Boggio, Abiy Woldetsadik, Chiara Dianzani, Daniele Sblattero, Annalisa Chiocchetti, Junji 
Yagi, Josè M. Rojo, Umberto Dianzani 
 
Abstract 
 
ICOS and CD28 are expressed by T cells and are involved in costimulation of cytokine production 
in T helper (TH) cells. ICOS binds B7h expressed by several cell types, whereas CD28 binds B7.1 
and B7.2 expressed by activated antigen presenting cells. This work investigated the role of B7h 
and B7.1 in TH17 and TH9 cell differentiation by assessing activity of recombinant B7h-Fc and 
B7.1-Fc on human naïve TH cells activated in the presence of different combinations of exogenous 
cytokines. In the presence of TGF-β1 and IL-1β (TH17 promoting condition), B7h-Fc was more 
effective than B7.1-Fc in inducing IL-17A and IL-10 secretion, whereas B7.1-Fc was more effective 
in inducing IL-17F. Dual costimulation with B7h-Fc and B7.1-Fc displayed an intermediate pattern 
with predominance of IL-17F over IL-17A, secretion of high levels of IL-10, and secretion of IL-9 
levels lower than those induced by B7.1-Fc alone. In the presence of TGF-β1 and IL-4 (TH9 
promoting condition), B7h-Fc induced IL-17A only, whereas B7.1-Fc induced also IL-17F, IL-10, 
and high levels of IL-9. Experiments on memory TH cells showed that B7h-Fc mainly supported 
secretion of IL-17A and IL-10, whereas B7.1-Fc supported secretion of IL-17A, IL-17F, IL-10, and 
IL-9. These data indicate that B7h and B7.1 play different roles in modulation of TH17 and TH9 
differentiation. This plasticity might be important in the immune response to pathogens and tumors, 
and in the development of autoimmune diseases, and should be taken in consideration in 
designing of immunotherapeutic protocols triggering ICOS or CD28. 
Abbreviations 
TH, T helper;  APC, antigen-presenting cells; TCR, T cell receptor;  mAbs, monoclonal 
antibody;  PBMC, peripheral blood mononuclear cells; ICOS, inducible costimulator; TGF-
β, transforming growth factor-β; IL-, interleukine-; INF-γ, interferon-γ;  PB,peripheral 
blood; Ig, immunoglobulin 
1. Introduction 
Activation and differentiation of naïve T helper (TH) cells requires three signals from antigen-
presenting cells (APC). The first is delivered through the T cell receptor (TCR) upon recognition of 
the antigenic peptide presented by the appropriate MHC molecule, the second by T cell 
costimulatory molecules engaged by their ligands expressed on APC, and the third by cytokines in 
the microenvironment [1] and [2]. 
The best known TH cell costimulatory molecule is CD28, which is constitutively expressed by all 
TH cells, binds B7.1 (CD80) and B7.2 (CD86) on APC, and promotes cell proliferation and cytokine 
secretion [3], [4] and [5]. Another TH costimulator is ICOS (CD278), which belongs to the CD28 
family and is selectively expressed by activated T cells [6], [7] and [8]. It binds B7h (CD275, B7H2, 
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B7-RP1, ICOSL, GL50) expressed by both haematopoietic and non-haematopoietic cells. B7h is 
constitutively expressed by B cells, macrophages, and dendritic cells, but it is also expressed by 
vascular endothelial cells, epithelial cells, and fibroblasts; ICOS-mediated triggering of B7h 
modulates adhesiveness of vascular endothelial cells to inflammatory and tumor cells [9] and [10]. 
This expression pattern suggests that the ICOS:B7h interaction has a role in both T cell activation 
in lymphoid organs and the control of T cell function at sites of inflammation[11]. In TH cells, ICOS 
function appears to modulate cytokine secretion by acting on recently activated/memory cells, 
whereas it is less effective in naïve TH cells, whose activation seems to depend primarily on CD28 
costimulation [12], [13], [14], [15],[16] and [17]. 
To date, four types of effector TH cells are generally recognized, namely TH1, TH2, TH17, and 
Treg cells, characterized by secretion of different patterns of cytokines [18]. Under certain 
circumstances, these patterns may switch from that of one lineage toward another suggesting that 
TH cells are plastic depending on the inflammatory conditions[19]. Their differentiation from naïve 
TH cells depends on the cytokine environment during activation, but a role may also be played by 
the costimulatory receptors delivering the “second signal”. For instance, CD28 costimulation 
induces secretion of high amounts of IL-2 supporting most types of T cells, whereas ICOS 
costimulation is incapable to induce IL-2 but potently induces IL-10 secretion. Moreover, 
substantial differences have been reported in humans and mice since ICOS triggering induces 
secretion of high amounts of IL-4 in mice but IFN-γ in humans, which are associated with TH2 and 
TH1 cells respectively [20], [21], [22], [23], [24] and [25]. These differences might be partly due to 
the capacity of the human but not the mouse B7h to weakly interact with CD28 and CTLA4, using 
binding sites different from that used by ICOS [26]. 
Recent data showed that ICOS and CD28 may also play a different role in differentiation of TH17 
cells, which are involved in the immune response against certain parasites and in some 
autoimmune diseases [27], [28], [29] and [30]. In humans, they are characterized by the production 
of IL-17A, IL-17F, IL-21, IL-22, and IL-26 and their differentiation is dependent on the transcription 
factor retinoic acid-related orphan nuclear receptor C2 (RORC2) [31]. TH17 differentiation is 
controlled by several cytokines and is inhibited under TH1 and TH2 polarizing conditions, i.e. 
presence of IFN-γ and IL-4, respectively. In mice, TH17 differentiation requires TGF-β1 and IL-6, is 
amplified in an autocrine fashion by IL-21, and is further promoted by IL-23 [32]. In humans, TH17 
differentiation involves the same cytokines, but their relative contributions are 
debated [31], [33], [34], [35],[36] and [37]. 
Early reports suggested that both ICOS and CD28 were involved in TH17 differentiation in 
mice [28] and [38]. More recently, studies using ICOS-deficient mice indicated that ICOS was 
dispensable for TH17 differentiation, but it was necessary for TH17 cells to attain full effector 
functions [39]. In humans, ICOS was found to be more effective than CD28 in inducing IL-17A and 
IL-17F secretion in peripheral blood (PB) “memory” TH17 (CCR4+CCR6+), Treg 
(CD25+CD127loFoxP3+), and TFH (CXCR5+CD45RO+) cells, but not in TH1 (CXCR3+CCR4-
CCR6+) and TH2 (CCR4+CXCR3−CCR6−) cells [40]. Moreover, in long-term cultures, ICOS but not 
CD28 triggering was capable to support development of TH17 cells from umbilical cord blood naïve 
TH cells (CD4+CD45RA+CD25−) but only in the presence of a TH17-polarizing milieu containing 
TGF-β1, IL-6, IL-1β, IL-23, and neutralizing antibodies to IFN-γ and IL-4 [40]. 
TH cells generated under TH17-promoting conditions comprises not only IL-17 secreting cells, but 
also cells secreting IL-9, exerting its activity on several cell types including T cells, mast cells, 
eosinophils, and epithelial cells. IL-9 secretion has been initially ascribed to TH2 cells, but recent 
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reports described a distinct subset of TH9 cells characterized by secretion of IL-9 and IL-10, 
lacking secretion of IFN-γ, IL-4, and IL-17, and involved in development of allergic airway disease 
and in the response to parasitic infections [19]. However, IL-9 production is not unique to such cells 
since it may also be expressed by Tregs and TH17 cells [18]. TH9 cell differentiation is supported 
by CD28 costimulation and requires presence of TGF-β1 and IL-4, whereas no data are available 
on the role of ICOS. 
This work compared the activity of fusion proteins of the extracellular portion of human B7h or B7.1 
fused to the human IgG1 Fc (i.e. B7h-Fc and B7.1-Fc) and dissected the role of the cytokine 
microenvironment in induction of TH17 and TH9 cytokine secretion in short term cultures of PB 
naïve TH cells from adult donors. The aim was to provide information helping to understand the 
variable effects that these reagents have when used as systemic or local immune modulators in 
vivo. Results showed that B7h-Fc was more effective than CD28 in induction of IL-17A and IL-10, 
whereas B7.1-Fc was more effective in induction of IL-17F and IL-9. The minimal cytokine 
microenvironment to obtain these responses was presence of TGF-1β plus either IL-1β or IL-4, but 
IL-6 and IL-21 further supported production of these cytokines. 
 
 
2. Materials and methods 
2.1. Cells 
Peripheral blood mononuclear cells (PBMC) were obtained by density gradient centrifugation from 
buffy coats provided by the local Blood Transfusion Service (Novara, Italy). Naïve CD4+ T cells 
were purified by panning to remove CD11b+, CD45RO+, CD25+, CD19+, and HLA-DR+ cells with 
the appropriate monoclonal antibody (mAbs), followed by use of the CD4+ T Cell Isolation Kit II 
(Miltenyi Biotec) or directly with CD4+ T naïve Cell Isolation Kit II (Miltenyi Biotec). This approach 
provided >97% cells displaying the phenotype CD3+CD4+CD45RA+CD14−CD16−, as assessed by 
direct immunofluorescence and flow cytometry. 
CD4+CCR6+ were purified by using the CD4+ T Cell Isolation Kit II (Miltenyi Biotec) followed by 
positive selection with a PE-conjugated anti-CCR6 mAb and anti-PE magnetic beads (Miltenyi 
Biotec). CD4+CD45RO+ were purified by using the Memory CD4+ T Cell Isolation Kit (Miltenyi 
Biotec). 
2.2. TH cell differentiation assay 
Round-bottom 96-well plates were coated with 100 μl of anti-CD3 mAb (OKT3) overnight at 4 °C. 
To stimulate ICOS or CD28, plates were washed with PBS and further coated with B7h-Fc 
(5 μg/ml; R&D System) or B7.1-Fc (5 μg/mL; R&D System) for 2 h at room temperature. 
Plates were then washed with PBS and purified naïve CD4+ T cells were seeded at 105 cells/well in 
triplicate in 200 μl of in RPMI 1640 (Gibco) plus 10% FCS, or EX-VIVO 20 Serum Free (Lonza). 
Where indicated, cultures were performed in the presence of the following recombinant cytokines: 
IL-1β and IL-4 (10 ng/ml; PeproTech), IL-6 (20 ng/ml; PeproTech), IL-21 (100 ng/ml; Immunotools), 
IL-23 (20 ng/ml; R&D Systems), and TGF-β1 (5 ng/ml; R&D Systems). In some experiments, 
neutralizing antibodies against TGF-β1 (10 μg/ml; R&D Systems), IL-1β (4 μg/ml; R&D Systems), 
IL-4 (4 μg/ml; R&D Systems), and IFN-γ (8 μg/ml; R&D Systems) were added to the cultures. To 
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analyze cytokine secretion, supernatants were collected at day 5 of culture and standard enzyme-
linked immunosorbent assays (ELISA) were used to evaluate secretion of IL-17A (R&D Systems), 
IL-17F, IL-17A/F, IL-9 (eBioscience), and IL-10 (Biolegend). 
2.3. Real-time PCR 
Total RNA was extracted and transcribed to cDNA with Cells-to-cDNA II Kit (Ambion) from cells 
collected at day 5 of culture after re-stimulation with PMA (50 ng/mL, Sigma–Aldrich) plus 
Ionomycin (1 μg/mL, Sigma–Aldrich) for the last 5 h. Transcripts were quantified by real-time PCR 
on an ABI PRISM 7000 sequence detector (Applied Biosystems) with Applied Biosystems 
predesigned TaqMan Gene Expression Assays in duplicate for each sample. Relative 
quantification was performed using the comparative ΔΔCT method. 
The following probes were used (Applied Biosystems assay identification numbers in parentheses): 
IL-17A (Hs00174383_m1), IL-17F (Hs00369400_m1), RORc (Hs01076112_m1), IL-26 
(Hs00218189_m1), PU.1 (Hs02786711_m1). For each sample, mRNA abundance was normalized 
to the amount of ribosomal protein HPRT (Hs99999909_m1). 
2.4. Intracellular staining 
Cytokine-producing cells were stained after stimulation with PMA (20 ng/mL, Sigma–Aldrich) plus 
Ionomycin (2 μg/mL, Sigma–Aldrich) for 6 h in the presence of Brefeldin A (10 μg/ml, Sigma–
Aldrich). After fixation with 2% paraformaldehyde (Sigma–Aldrich), cells were permeabilized with 
PBS/1% Saponin (Sigma–Aldrich) and stained using anti-IL-17A mAb (IgG1) conjugated with APC 
(eBioscience), anti-IL-17F mAb (IgG1) conjugated with PE (eBioscience), anti-IL-10 mAb (IgG1) 
conjugated with PE (Miltenyi Biotec), anti-IFNγ mAb (IgG2b) conjugated with FITC (eBioscience), 
and ROR-γt mAb (IgG2b) conjugated with APC (eBioscience), and the isotype-matched Ig controls 
(eBioscience). 
2.5. Statistical analysis 
The non-parametric paired Wilcoxon test was used to compare differences in all experiments. 
Values of P < 0.05 were considered statistically significant. 
3. Results 
3.1. Differential effect of costimulation mediated by B7h-Fc and B7.1-Fc on expression of 
TH17-related cytokines 
To investigate the cytokine milieu necessary to support IL-17A secretion in naïve TH cells, we 
analyzed IL-17A secretion induced by B7-Fc in the presence of different combinations of 
recombinant cytokines. Experiments were performed in the absence of neutralizing antibodies to 
IL-4 and IFN-γ, often used to increase IL-17 secretion, to allow these cytokines to endogenously 
influence the cell response. Purified PB naïve TH cells were incubated in serum free medium in 
wells pre-coated with anti-CD3 mAb in the presence and absence of B7h-Fc and different 
combinations of exogenous TGF-β1, IL-1β, IL-6, IL-21, and IL-23. Fig. 1 shows the data obtained 
in the presence of B7h-Fc. It shows that IL-17A secretion was always undetectable in the absence 
of TGF-β1. In the presence of TGF-β1, IL-1β or IL-21 were able to induce IL-17A, with a higher 
induction observed in the presence of both the exogenous cytokines. In contrast, IL-6 and IL-23 did 
not induce IL-17A secretion even in the presence of TGF-β1 and did not increase secretion 
induced by TGF-β1 + IL-21, but they increased secretion induced by TGF-β1 + IL-1β (Fig. 1). B7h-
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Fc was crucial for this response since IL-17A secretion was never detected when cells were 
activated using the anti-CD3mAb alone (data not shown). 
 
 
 
Then, we compared the effect of B7h-Fc and B7.1-Fc on IL-17A secretion in PB naïve TH cells and 
we extended the analysis to IL-17F, the IL-17A/F heterodimer, and IL-10, which can be secreted by 
TH17 cells. Naïve CD4+ T cells were activated with anti-CD3 mAb plus either B7h-Fc or B7.1-Fc 
and were cultured in the presence or absence of TGF-β1 + IL-1β together with either IL-6, or IL-21, 
or IL-23, or the three cytokines combined. ELISA analysis of the culture supernatants showed that 
B7h-Fc was more efficient than B7.1-Fc in inducing IL-17A (Fig. 2A) and IL-10 (Fig. 2C) secretion 
in the presence of TGF-β1 + IL-1β with or without the other cytokines. In B7h-Fc costimulated cells, 
IL-10 secretion was substantially increased by addition of either IL-6 or IL-21 to the culture 
medium. Conversely, IL-17F secretion was induced to higher levels by B7.1-Fc than by B7h-Fc 
provided that TGF-β1 and IL-1β were supplemented with at least one of the other cytokines (Fig. 
2B). By contrast, secretion of the IL-17A/IL-17F heterodimer was undetectable in all culture 
conditions (data not shown). 
 
 6 
 
 
Fig. 2.  
Secretion of IL-17A, IL-17F, and IL-10 induced in naïve CD4+ T cells by costimulation with B7h-Fc or B7.1-Fc. 
Naïve CD4+ T cells were stimulated with anti-CD3 plus either B7h-Fc or B7.1-Fc in the presence of different 
combinations of TGF-β1, IL-1β, IL-6, IL-21, and IL-23. Secretion of IL-17A (A), IL-17F (B) and IL-10 (C) was 
assessed by ELISA in the supernatants at day 5. Results are expressed as mean ± SD from six experiments. (*) 
Marks significant differences (p < 0.05) between B7h-Fc and B7.1-Fc costimulated cells in each cytokine milieu. 
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To determine if these effects were manifested at transcriptional level, we evaluated expression of 
the IL-17A and IL-17F mRNA by real time PCR in cells activated for 5 days using the conditions 
above followed by reactivation with PMA + Ionomycin for 5 h. This analysis was also extended to 
the IL-26 mRNA which is also expressed by human TH17 cells. IL-17A mRNA analysis (Fig. 3A) 
was largely in agreement with the protein data since B7h-Fc significantly induced higher levels of 
IL-17A mRNA than B7.1-Fc in the presence of TGF-β1 + IL-1β with either IL-6, or IL-21, or IL-23. 
IL-17F mRNA analysis (Fig. 3B) paralleled the protein data since B7.1-Fc significantly induced 
higher levels than B7h-Fc under all culture conditions where TGF-β1 + IL-1β were present. IL-26 
mRNA was induced to relatively low levels, but induction was higher with B7.1-Fc than with B7h-
Fc. Moreover, the IL-26 mRNA was induced at the highest levels when all recombinant cytokines 
were present in both B7h- and B7.1-costimulated cells (Fig. 3C). 
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Fig. 3.  
Expression of the IL-17A, IL-17F, and IL-26 mRNA induced in naïve CD4+ T cells by costimulation with B7h-Fc or B7.1-
Fc. Naïve CD4+ T cells were stimulated as in Fig. 2 and mRNA encoding for IL-17A (A), IL-17F (B), and IL-26 (C) was 
evaluated by real time PCR at day 5 after re-stimulation with PMA/Ionomycin for the last 5 h; cycling threshold values 
were normalized to those of mRNA encoding HPRT, and expression detected in B7.1-Fc-treated cells was set as 1.0. 
Results are expressed as mean ± SD from six experiments. (*) Marks significant differences (p < 0.05) between B7h-Fc 
and B7.1-Fc costimulated cells in each cytokine milieu. 
 
3.2. Differential effect of B7h-Fc and B7.1-Fc on expression of TH9-related cytokines 
Differentiation of TH9 cells requires presence of TGF-β1 + IL-4, but IL-9 secretion can also be 
induced, at lower levels, in the presence of TGF-β1 + IL-1β [19]. Therefore, we compared ability of 
B7h-Fc and B7.1-Fc to induce secretion of IL-9, IL-10, IL-17A, and IL-17F in the presence of either 
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TGF-β1 + IL-1β or TGF-β1 + IL-4. Moreover, we assessed the effect of the dual costimulation with 
B7h-Fc + B7.1-Fc in the same conditions to assess the reciprocal interference of the two costimuli. 
PB naïve CD4+ T cells were activated with anti-CD3 mAb plus B7h-Fc and/or B7.1-Fc and cultured 
with either TGF-β1 + IL-1β (TH17 promoting conditions) or TGF-β1 + IL-4 (TH9 promoting 
conditions) in the presence and absence of IL-6 + IL-21 supporting both TH17 and TH9 
cells [35],[41] and [42]. Secretion of IL-17A, IL-17F, IL-10, and IL-9 was then assessed by ELISA in 
the culture supernatants (Fig. 4). 
 
Fig. 4.  
Expression of IL-9, IL-10, IL-17A, and IL-17F induced in naïve CD4+ T cells by costimulation with B7h-Fc and/or B7.1-Fc 
in TH17- and TH9-promoting conditions. Naïve CD4+ T cells were stimulated with anti-CD3 plus either B7h-Fc and/or 
B7.1-Fc in the presence of different combinations of TGF-β1, IL-1β or IL-4, IL-6, and IL-21. Cytokine secretion was 
evaluated by ELISA after 5 days of culture. Results are expressed as mean ± SD from six experiments. (*) Marks 
significant differences from costimulation of B7h-Fc alone; (#) marks significant differences from costimulation of B7.1-Fc 
alone. 
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In the presence of TGF-β1 + IL-1β, B7h-Fc induced levels of IL-9 secretion that were similar to 
those induced by B7.1-Fc. Secretion of IL-17A, IL-17F, and IL-10 induced by B7h-Fc or B7.1-Fc 
were in line with those shown in the previous experiments. The dual use of B7h-Fc + B7.1-Fc 
increased secretion of IL-10 and, at a lesser extent, IL17A, but decreased secretion of IL-9 
compared with the effect exerted by either B7h-Fc or B7.1-Fc. Addition of IL-21 + IL-6 did not 
change the pattern of IL-9 secretion, and the effect exerted on secretion of IL-17A, IL-17F, and IL-
10 was in line with that shown in the previous experiments. In these conditions, the dual use B7h-
Fc + B7.1-Fc induced high secretion of IL-10 and IL-17F, and low secretion of IL-17A similar to 
those induced by B7.1-Fc, and decreased secretion of IL-9 compared with the effect exerted by 
either B7h-Fc or B7.1-Fc. 
In the presence of TGF-β1 + IL-4, B7h-Fc induced secretion of lower levels of IL-9 and IL-10 than 
B7.1-Fc, whereas IL-17A secretion was similarly induced by each costimulus; dual use of B7h-
Fc + B7.1-Fc decreased secretion of IL-9, but increased secretion of IL-10 compared to the effect 
exerted by B7.1-Fc alone; IL-17F was almost undetectable with any stimulus. When also IL-
21 + IL-6 were added to the cultures, B7h-Fc still induced secretion of minimal levels of IL-9, IL-10, 
and IL-17F, but it induced similar levels of IL-17A as B7.1-Fc; by contrast, B7.1-Fc induced 
substantial levels of all cytokines; dual use of B7h-Fc + B7.1-Fc increased secretion of IL-10 and, 
at a lesser extent, IL-17A but it decreased secretion of IL-9 and had no effect on secretion of IL-
17F compared to the effect exerted by B7.1-Fc alone. 
To further investigate the influence of the cytokine milieu, we assessed the effect of neutralizing 
antibodies to IL-4, IFNγ, IL-1β, and TGF-β1 on secretion of IL-17A, IL-17F, IL-9, and IL-10 by cells 
activated with the different costimuli in the presence of exogenous TGF-β1 + IL-1β + IL-6 + IL-
21. Fig. 5 shows that neutralization of either TGF-β1 or IL-1β abrogated secretion of IL-17A, IL-
17F, and IL-9 and decreased secretion of IL-10 in all costimulation settings. Neutralization of IL-
4 + IFNγ substantially increased secretion of IL-17A and inhibited secretion of IL-10 in all 
costimulation settings but especially in those costimulated with B7h-Fc alone; moreover, it slightly 
increased secretion of IL-17F in the cells costimulated with both costimuli, whereas it had no effect 
on secretion of IL-9 in any costimulation setting. 
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Fig. 5.  
Effect of neutralizing antibodies to IL-4, IFN-γ, IL-1β, and TGF-β1 on secretion of IL-17A, IL-17F, IL-9, and IL-10. Naïve 
CD4+ T cells were activated with the different costimuli in the presence of exogenous TGF-β1 + IL-1β + IL-6 + IL-21 and 
in the presence or absence of neutralizing antibodies to either TGF-β1, or IL-1β, or IL-4 + IFNγ. Cytokine secretion was 
evaluated by ELISA after 5 days of culture. Results are expressed as mean ± SD from six experiments. (*) Marks 
significant differences from the corresponding costimulation setting in the absence of neutralizing antibodies. 
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3.3. Induction of the RORC2 and PU.1 transcription factors 
The transcription factors RORC2/ROR-γt and PU.1 are involved in differentiation of TH17 and TH9 
cells respectively. To further address the effect of B7h-Fc in TH17 and TH9 differentiation, we 
analyzed its capacity to support expression of Rorc2 and PU.1mRNA in naïve TH cells activated in 
TH17 and TH9 conditions as described above. 
In the presence of TGF-β1 + IL-1β, B7h-Fc induced similar levels of the Rorc2 mRNA as B7.1-Fc, 
and copresence of both costimuli substantially increased these levels. In the further presence of IL-
6 + IL-21, B7h-Fc induced similar levels of the Rorc2 mRNA as B7.1-Fc, but copresence of both 
costimuli decreased these levels ( Fig. 6A), which was in line with the decreased IL-17A secretion 
detected in this condition (Fig. 4C). By contrast, the PU.1 mRNA was always barely detectable 
(data not shown). 
 
Fig. 6.  
Rorc2 and PU-1 mRNA expression induced by naïve CD4+ T cell costimulation with B7h-Fc or B7.1-Fc. Experiments 
were performed as in Fig. 3 and levels of mRNA encoding for RORC2 and PU.1 were evaluated by real time PCR. 
Results are expressed as mean ± SD from six experiments. (*) Marks significant differences from costimulation of B7h-Fc 
alone; (#) marks significant differences from costimulation of B7.1-Fc alone.  
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In the presence of TGF-β1 + IL-4, both the Rorc2 and the PU.1 mRNAs were detectable only in the 
further presence of IL-6 + IL-21.  
In these conditions, Rorc2 was induced at higher levels by B7.1-Fc than by B7h-Fc and these 
levels were substantially increased by costimulation of both receptors ( Fig. 6A), which was in line 
with the increased IL-17A secretion detected in this condition (Fig. 4C); PU.1 was detectable only 
using B7.1-Fc (Fig. 6B), which was in line with high IL-9 secretion detected in this condition (Fig. 
4A). 
3.4. Effect of B7h-Fc and B7.1-Fc in memory T cells 
To evaluate the effects of B7h-Fc and B7.1-Fc in memory T cells, we used two T cell preparations: 
CD4+CCR6+ T cells which comprise memory TH cells producing IL-17 [43], and CD4+CD45RO+ TH 
cells which comprise whole TH memory cells. Cells were activated as described above and 
cultured with a cytokine cocktail composed of TGF-β1, IL-6, and IL-21 supplemented with either IL-
1β (TH17 promoting conditions) for CD4+CCR6+ cells, or IL-4 (TH9 promoting conditions) for 
CD4+CD45RO+ cells. Secretion of IL-17A, IL-17F, IL-10, IL-9, and the IL-17A/F heterodimers was 
then evaluated by ELISA in the supernatants. 
In CD4+CCR6+ cells, B7h-Fc induced higher amounts of IL-10 and lower amounts of IL-17F, IL-
17A/F and IL-9 than B7h-Fc. Dual use of B7h-Fc + B7.1-Fc increased secretion of IL-10, whereas 
secretion of IL-9 was intermediate between those induced by each costimulus alone; secretion of 
IL-17F and the IL-17A/F heterodimer was similar to that induced by B7.1-Fc. Secretion of IL-17A 
was induced at similar levels by all costimuli (Fig. 7). 
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Fig. 7.  
Secretion of IL-17A, IL-17F, IL-17A/F, IL-9 and IL-10 induced in “memory” TH cells by costimulation with B7h-Fc or B7.1-
Fc. CD4+CCR6+ and CD4+CD45RO+ “memory” T cells were stimulated as in Fig. 2 in the presence and absence of a 
cytokine cocktail of TGF-β1, IL-1β, IL-6, IL-21, and IL-23; secretion of IL-9 (A), IL-10 (B), IL-17A (C), IL-17F (D) and IL-
17A/F (E) was assessed by ELISA in the supernatants at day 5. Results are expressed as mean ± SD from six 
experiments. (*) Mark significant differences from costimulation of B7h-Fc alone; (#) mark significant differences from 
costimulation of B7.1-Fc alone 
In CD4+CD45RO+ T cells, B7.1-Fc induced higher levels of IL-9 and IL-10 than B7h-Fc and these 
levels were further increased by use of both costimuli. All costimuli induced similar high levels of 
IL-17-A and minimal levels of IL-17F and IL-17A/F (Fig. 7). 
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3.5. Single cell analysis of IL-17A, IL-17F, and IL-10 production 
To assess whether IL-17A was produced by the same cells producing IL-10 or IL-17F, we 
performed a two-color intracellular staining and cytofluorimetric analysis in both naïve TH cells and 
“memory” CD4+CCR6+ TH cells. B7h-Fc and B7.1-Fc costimulated cells were cultured for 5 days in 
the presence of a cytokine-cocktail containing TGF-β1, IL-1β, IL-6, IL-21, and IL-23. Cells were 
then re-activated with PMA and Ionomycin in the presence of Brefeldin A and stained for 
intracellular IL-17A and either IL-17F or IL-10. 
Analysis of naïve TH cells showed that B7h-Fc induced higher proportion of IL-17A+ cells and 
lower proportions of IL-17F+ cells than B7.1-Fc (Fig. 8A). B7h-Fc and B7.1-Fc induced comparable 
proportions of IL10+ single positive cells (Fig. 8B). The small proportions of positive cells detected 
in these experiments are in line with those reported by other authors [36]. Minimal proportions of 
cells were either IL-17A+/IL-17F+ or IL-17A+/IL-10+ double positive in all costimulation settings. 
Moreover, these cells were also stained for intracellular expression of either IFN-γ or ROR-γt, 
which showed that both B7h-Fc and B7.1-Fc induced high expression of ROR-γt (Fig. 8E) and no 
production of IFN-γ (Fig. 8D). The discrepancy between the high proportions of ROR-γt+ cells and 
the low proportions of IL-17A+ or IL-17F+ cells is not surprising since ROR-γt+ expression may not 
be sufficient for TH17 cell differentiation which also involves other transcription factors, such as 
RORa [44], IRF4 [45], and Batf [46]. Analysis of CD4+CCR6+ cells showed that B7h-Fc induced 
higher proportion of IL-17A+ cells and lower proportions of IL-17F+ cells than B7.1-Fc. A substantial 
population of IL-17A+/IL-17F+ double positive cells were induced by both B7h-Fc and B7.1-Fc (Fig. 
8G). The proportion of IL-10+ cells was low and it was similar in the cells costimulated with either 
B7h-Fc or B7.1-Fc; IL-17A+/IL-10+ double positive cells were almost absent (Fig. 8H). 
 
Fig. 8.  
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Cytofluorimetric analysis of intracellular expression of IL-17A, IL-17F, IL-10, IFN-γ, and ROR-γt. Naïve CD4+ T cells (A, 
B, D, and E), and CCR6+CD4+ T cells (G and H) were cultured as described in Fig. 3 in the presence of a cytokine 
cocktail of TGF-β1, IL-1β, IL-6, IL-21, and IL-23 for 5 days; IL-17A+ and either IL-17F+ or IL-10+ cells were evaluated by 
two-color intracellular staining after a 6 h re-stimulation with PMA/Ionomycin in the presence of Brefeldin A. Control 
staining with the isotype-matched control Ig is shown in C, F, and I. The proportion of each population are indicated 
within the quadrants. Data are from one representative experiment out of four experiments.  
 
4. Discussion 
This work shows that costimulation with B7h-Fc or B7.1-Fc have different effects on secretion of 
TH17 and TH9 cytokines in naïve TH cells. The overall data indicate that B7h-Fc is more selective 
than B7.1-Fc since it exerts a preferential effect on IL-17A and IL-10, whereas B7.1-Fc is highly 
effective on IL-17F and IL-9 too. 
In naïve TH cells, the minimal cytokine milieu to induce secretion of both TH17 and TH9 cytokines 
included TGFβ1 + IL-1β, whose effect was potentiated by a cocktail composed of IL-6 and IL-21. In 
these conditions, B7h-Fc induced secretion of IL-17A and IL-10 more efficiently than B7.1-Fc, 
which in turn induced higher secretion of IL-17F and expression of the IL-26 mRNA; by contrast, 
secretion of IL-9 was similarly induced by the two costimuli. Secretion of IL-17A and IL-10 were 
differentially sensitive to TH1- and TH2-polarizing cytokines since neutralization of IFN-γ and IL-4 
strikingly increased secretion of IL-17A and decreased secretion of IL-10, especially in the cells 
costimulated with B7h-Fc. When IL-1β was substituted with IL-4, the most striking response was 
the secretion of high levels of IL-9 induced by B7.1-Fc but not by B7h-Fc, which in turn displayed a 
selective effect in induction of IL-17A. By contrast, B7.1-Fc induced also secretion of IL-10, IL-17A, 
and low levels of IL-17F. 
Memory TH cells, too, responded differently to B7h-Fc and B7.1-Fc, and B7h-Fc was more 
selective than B7.1-Fc in inducing cytokine secretion. In CD4+CCR6+ cells cultured in TH17 
promoting conditions, B7h-Fc induced similar levels of IL-17A as B7.1-Fc, but it induced higher 
levels of IL-10 and lower levels of IL-17F and IL-9 than B7.1-Fc. In CD4+CD45RO+ cells cultured in 
TH9 promoting conditions, B7h-Fc induced high levels of IL-17A only, whereas B7.1-Fc induced 
high levels of IL-9 and IL-10 too. 
Dual costimulation with B7h-Fc + B7.1-Fc influenced these patterns in a complex manner and 
displayed different effects in different cytokine milieus. In most culture conditions, it increased 
secretion of IL-10 and decreased secretion of IL-9, whereas the effect on secretion of IL-17A was 
variable in the different conditions. 
Secretion of IL-17F was more dependent on the cytokine milieu than that of IL-17A since it 
required that the minimal milieu, containing either TGFβ1 + IL-1β or TGFβ1 + IL-4, was enriched 
with at least IL-6 and/or IL-21. Moreover, presence of exogenous IL-4 substantially decreased 
secretion of IL-17F in all culture conditions, whereas it had no substantial effect on secretion of IL-
17A. 
In naïve TH cells, neither B7h-Fc nor B7.1-Fc induced secretion of IL-17A/F heterodimers even 
when substantial amounts of both IL-17A and IL-17F were induced. In contrast, especially when 
costimulated with B7.1-Fc, substantial amounts of the heterodimer were produced by “memory” 
CCR6+ TH17 cells. These data suggest that IL-17A and IL-17F were produced by distinct cell 
subsets in the naïve TH cell cultures, whereas memory TH cells comprised substantial amounts of 
 
 17 
cells producing both cytokines. In line with this possibility, IL-17A+/IL-17F+ double positive cells 
were almost absent in the naïve TH cell cultures, whereas they were present in the “memory” 
CD4+CCR6+ T cell cultures. Moreover, the single cell analyses showed that also IL-17A and IL-10 
were produced by distinct subsets of cells, since IL-17A+/IL-10 double-positive cells were always 
almost absent. 
IL-17A and IL-17F are homodimers sharing about 50% sequence identity and several biological 
activities including the induction of proinflammatory cytokines and antimicrobial peptides, 
neutrophil recruitment, mucosal immunity against extracellular pathogens, and an involvement in 
several autoimmune diseases [29] and [30]. However, certain features distinguish these two 
cytokines. Specifically, the ability to upregulate transcription factors and proinflammatory molecules 
appears lower for IL-17F than for IL-17A. Furthermore, IL-17A but not IL-17F appears to play a role 
in development of collagen-induced arthritis, contact hypersensitivity, and delayed-type 
hypersensitivity[47]. In the mouse model of OVA-alum induced asthma, IL-17A promotes the TH2 
response, whereas IL-17F has a regulatory role in restricting allergic asthma development. In 
contrast, in dextran sulfate sodium-induced colitis, IL-17A played a protective role, whereas IL-17F 
appeared to exacerbate the intestinal inflammation. In multiple sclerosis lesions, IL-17A but not IL-
17F was detected [48]. Finally, in gastric adenocarcinoma, IL-17A induced activation of MAPK, AP-
1, and NF-κB, and secretion of high amounts of IL-8, whereas IL-17F induced activation of NF-κB 
alone and secretion of low amounts of IL-8 [48]. IL-17 receptor usage, too, has been reported to be 
partly different since IL-17A seemed to preferentially interact with IL-17RA, whereas IL-17F with IL-
17RC [49]. Plasmon resonance experiments showed that IL-17A, IL-17F, and IL-17A/F 
heterodimers bound to IL-17RC with comparable affinities, but with different affinities to IL-17RA 
where the affinity for IL-17A highest, IL-17F lowest, and intermediate for the heterodimer. 
Moreover, biological activity of IL-17A was primarily inhibited by soluble IL-17RA, IL-17F by soluble 
IL-17RC, and IL17A/F heterodimer by both receptors[50]. 
Paulos et al. [40] reported that ICOS triggering is a potent inducer of IL-17A secretion in umbilical 
cord blood naïve TH cells in the presence of a TH17-polarizing milieu containing IL-1β, IL-6, IL-23, 
neutralizing antibodies to IFN-γ and IL-4. By contrast, triggering of CD28 and dual costimulation of 
CD28 + ICOS were poorly effective in inducing IL17A secretion. Moreover, IL-10 secretion was 
induced at comparable levels by each costimulus. The inconsistencies with our results may partly 
depend on the different TH cell source since naïve cord blood TH cells include high proportions of 
recent thymic emigrant cells, which may influence the response and are rare in adult PBMC [51]; 
moreover, their stimulation protocols were different from ours since they triggered CD28 and ICOS 
by means of either mAb or cells transfected with the costimulatory ligands and expanded cells in 
long term (15 days) cultures using serum-containing medium. 
Both CD28 and ICOS signaling uses PI3 K but their different signaling outcomes may be due to the 
ability of CD28, but not ICOS, to bind the Grb-2/GADS adaptor proteins and the Itk and Lck 
kinases, and their differential usage of PI3 K subunits [52]. Moreover, ICOS costimulation has been 
reported to induce higher levels of NFATc1 than CD28 costimulation [21] which is intriguing at the 
light of the notion that NFATc1 activity is involved in induction of IL-17A, but not IL-17F [53]. 
5. Conclusion 
The overall data suggest that costimulation mediated by B7.1 triggers distinct effector functions 
depending on the cytokine microenvironment, i.e. it induces IL-17F secreting cells in the presence 
of TGFβ1 + IL-1β, and IL-9 secreting cells in the presence of TGFβ1 + IL-4. By contrast, 
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costimulation mediated by B7h is generally biased toward induction of IL-17A secreting cells and 
supports cell plasticity by favouring contemporary secretion of IL-10, which substantially modulates 
TH17 cell function [54]. IL-10 can be produced by several cell types, including TH1 and TH17 cells, 
where it negatively regulates their function and can be induced by strong TCR stimulation leading 
to sustained Erk activation [18]. This suggests that IL-10 serves to control the magnitude of many 
types of immune responses and to prevent tissue damage. This plasticity might be important in the 
immune response to pathogens and tumors, and in the development of autoimmune diseases, and 
should be taken in consideration in designing of immunotherapeutic protocols triggering ICOS 
and/or CD28. 
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